IMNP : Summary for Immune Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets close in 1 hr 42 mins

Immune Pharmaceuticals, Inc. (IMNP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.05+0.26 (+9.46%)
As of 2:18PM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.79
Bid2.98 x 100
Ask3.00 x 100
Day's Range2.65 - 3.17
52 Week Range0.12 - 5.02
Avg. Volume2,991,554
Market Cap28.17M
PE Ratio (TTM)-0.23
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • MarketWatchyesterday

    Immune Pharma shares tumble 9% premarket as it unveils restructuring

    Shares of Immune Pharmaceuticals Inc. slid 9% in premarket trade Monday, after the company unveiled a restructuring and said it has received notice from the Nasdaq that it is not in compliance with listing ...

  • PR Newswireyesterday

    Immune Pharmaceuticals Announces Corporate Restructuring

    In line with this prioritization, the Company's Board of Directors (the "Board") has authorized Dr. Daniel Teper to lead the Company's oncology business within the Company's Cytovia, Inc. subsidiary and to pursue a possible spin-off of Cytovia into a separate, stand-alone company independent from Immune.

  • PR Newswireyesterday

    Immune Receives Nasdaq Letter

    NEW YORK, April 24, 2017 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune") announced that on April 18, 2017 the Company has received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("Nasdaq") notifying that the Company does not comply with Nasdaq's filing requirements for continued inclusion set forth in Listing Rule 5250(c)(1) (the "Rule") because it had not yet filed its Form 10-K for the year ended December 31, 2016.  The Company is working to complete the 2016 Form 10-K and will file it as soon as practicable. Normally, the Company would have 60 calendar days to submit a plan to regain compliance, which the Nasdaq could use as the basis for an extension of no more than 180 days to regain compliance.